中宠股份(002891) - 2021 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2021 was ¥560,025,402.84, representing a 50.19% increase compared to ¥372,870,873.38 in the same period last year[8]. - Net profit attributable to shareholders for Q1 2021 was ¥21,129,830.61, a significant increase of 155.46% from ¥8,271,218.87 in the previous year[8]. - The net profit after deducting non-recurring gains and losses was ¥20,047,634.07, up 184.37% from ¥7,049,741.19 year-on-year[8]. - The basic earnings per share for Q1 2021 was ¥0.1078, an increase of 121.36% compared to ¥0.0487 in the same period last year[8]. - The net profit for Q1 2021 was ¥32,478,247.93, compared to ¥16,969,843.38 in Q1 2020, reflecting a year-over-year growth of 91.5%[55]. - The total comprehensive income for Q1 2021 was CNY 27,463,410.90, compared to CNY 11,281,998.65 in the previous year, marking a growth of approximately 143%[57]. Cash Flow and Investments - The net cash flow from operating activities improved to -¥20,607,568.48, a 18.87% improvement from -¥25,700,520.24 in the previous year[8]. - The company reported a significant increase in cash recovered from investments, amounting to ¥33,314.72 million, a 3822.90% increase from ¥849.24 million in the previous period[23]. - The cash flow from investment payments surged by 1786.73% to ¥16,296.84 million, compared to ¥863.76 million, indicating increased investment activities[23]. - The net cash flow from investment activities was 97,412,887.09 CNY, compared to -27,573,933.65 CNY in the previous year, indicating a positive turnaround[65]. - The total cash inflow from investment activities was 334,516,021.72 CNY, significantly higher than 8,639,404.38 CNY in Q1 2020[65]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,494,917,115.05, a slight decrease of 0.32% from ¥2,502,840,080.12 at the end of the previous year[8]. - The total assets of the company as of March 31, 2021, were ¥1,970,766,158.38, slightly down from ¥1,971,850,397.79 at the end of 2020[52]. - Total liabilities decreased to 629,693,296.14 CNY from 666,213,327.45 CNY, a reduction of approximately 5.5%[46]. - The company's total equity increased to 1,865,223,818.91 CNY from 1,836,626,752.67 CNY, reflecting a growth of about 1.5%[48]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 22,293[12]. - The largest shareholder, Yantai Zhongxing Biotechnology Co., Ltd., holds 26.41% of the shares, totaling 51,790,500 shares[12]. Research and Development - Research and development expenses rose by 79.90% to ¥950.39 million, compared to ¥528.29 million, reflecting the company's commitment to increasing R&D investment[20]. - Research and development expenses for Q1 2021 were ¥9,503,858.98, an increase of 80.5% compared to ¥5,282,931.14 in Q1 2020, highlighting a focus on innovation[55]. Derivative Investments and Risk Management - The company reported a total investment amount in derivatives of RMB 6,864.48 million, with a net loss of RMB 38.35 million during the reporting period[27]. - The company's derivative investments accounted for 3.31% of the net assets at the end of the reporting period[27]. - The company emphasized the importance of risk management strategies for derivative trading, including credit risk and liquidity risk management[29]. - The independent directors supported the company's derivative trading activities aimed at hedging against currency and interest rate fluctuations[29]. Operational Efficiency - Operating costs increased by 55.40% to ¥43,746.50 million, up from ¥28,150.17 million, primarily due to the rise in revenue[20]. - The company's financial expenses decreased by 67.05% to ¥286.07 million, down from ¥868.11 million, due to reduced interest expenses[20]. - The company experienced a 158.76% increase in prepaid expenses, reaching ¥3,829.66 million, compared to ¥1,479.99 million, due to expanded business operations[20]. Miscellaneous - The company has engaged in entrusted financial management with a total amount of 19,497.51 million CNY, with no overdue amounts reported[34]. - The company has no significant non-operating fund occupation by controlling shareholders or related parties during the reporting period[36]. - There were no violations regarding external guarantees during the reporting period[35]. - The company did not conduct any research, communication, or interview activities during the reporting period[38].